Equities analysts predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report earnings per share of ($0.06) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for BioDelivery Sciences International’s earnings. The highest EPS estimate is ($0.01) and the lowest is ($0.25). BioDelivery Sciences International posted earnings per share of ($0.16) during the same quarter last year, which would indicate a positive year over year growth rate of 62.5%. The firm is scheduled to announce its next quarterly earnings report on Thursday, August 8th.

On average, analysts expect that BioDelivery Sciences International will report full-year earnings of ($0.14) per share for the current year, with EPS estimates ranging from ($0.42) to ($0.05). For the next fiscal year, analysts expect that the firm will report earnings of $0.25 per share, with EPS estimates ranging from $0.09 to $0.46. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. The firm had revenue of $19.77 million for the quarter, compared to analyst estimates of $19.60 million. BioDelivery Sciences International had a negative return on equity of 43.40% and a negative net margin of 42.09%.

Several equities analysts have recently commented on BDSI shares. BidaskClub lowered Xencor from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 11th. SunTrust Banks started coverage on Zoetis in a research note on Tuesday, March 19th. They set a “hold” rating and a $100.00 price target on the stock. Zacks Investment Research lowered HENGAN INTL GRP/ADR from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 21st. HC Wainwright restated a “neutral” rating on shares of Rewalk Robotics in a research note on Friday, March 15th. Finally, Cantor Fitzgerald set a $8.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Friday, May 10th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $6.20.

Shares of BioDelivery Sciences International stock traded up $0.01 during trading on Friday, hitting $4.07. 977,597 shares of the stock traded hands, compared to its average volume of 969,730. The stock has a market cap of $364.32 million, a price-to-earnings ratio of -5.58 and a beta of 0.47. The company has a current ratio of 2.88, a quick ratio of 2.57 and a debt-to-equity ratio of 1.90. BioDelivery Sciences International has a 52-week low of $2.35 and a 52-week high of $5.37. The firm’s fifty day moving average is $4.41.

In related news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $4.77, for a total transaction of $38,160.00. Following the sale, the director now owns 598,254 shares of the company’s stock, valued at $2,853,671.58. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Healthcare Master Fun Broadfin sold 1,800,000 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $5.00, for a total value of $9,000,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,429,743 shares of company stock worth $11,707,558. 8.94% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. Weiss Asset Management LP acquired a new stake in shares of BioDelivery Sciences International in the first quarter worth approximately $113,000. Nordea Investment Management AB acquired a new stake in shares of BioDelivery Sciences International in the first quarter worth approximately $845,000. Advisory Services Network LLC acquired a new stake in shares of BioDelivery Sciences International in the first quarter worth approximately $768,000. QCM Cayman Ltd. acquired a new stake in shares of BioDelivery Sciences International in the first quarter worth approximately $35,000. Finally, ClariVest Asset Management LLC acquired a new stake in shares of BioDelivery Sciences International in the first quarter worth approximately $2,571,000. 56.73% of the stock is currently owned by institutional investors.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Further Reading: How is the Producer Price Index calculated?

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.